KPTI Key Statistics, Chart & Performance
The current stock price of KPTI is 6.92 USD. In the past month the price decreased by -5.72%. In the past year, price decreased by -25.84%.
KPTI Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to KPTI. When comparing the yearly performance of all stocks, KPTI is a bad performer in the overall market: 71.32% of all stocks are doing better.
KPTI Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to KPTI. KPTI has a bad profitability rating. Also its financial health evaluation is rather negative.
KPTI Financial Highlights
Over the last trailing twelve months KPTI reported a non-GAAP Earnings per Share(EPS) of -14.51. The EPS decreased by -22.45% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -129.5% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
KPTI Forecast & Estimates
12 analysts have analysed KPTI and the average price target is 14.89 USD. This implies a price increase of 115.2% is expected in the next year compared to the current price of 6.92.
For the next year, analysts expect an EPS growth of -25.06% and a revenue growth -1.42% for KPTI
KPTI Ownership
About KPTI
Company Profile
Karyopharm Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. The company is headquartered in Newton, Massachusetts and currently employs 279 full-time employees. The company went IPO on 2013-11-06. The firm is engaged in the discovery, development and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. The company is developing and commercializing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead asset, XPOVIO (selinexor), is marketed in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. The firm is engaged in evaluating selinexor in certain hematological and solid tumor malignancies, including endometrial cancer, mycosis fungoides (MF) and diffuse large B-cell lymphoma (DLBCL). The Company’s product candidate, eltanexor, is an oral SINE compound like selinexor, that selectively blocks the nuclear export protein XPO1.
Company Info
KARYOPHARM THERAPEUTICS INC
85 Wells Avenue, Second Floor
Newton MASSACHUSETTS 02459 US
CEO: Michael G. Kauffman
Employees: 279
Phone: 16176580600
KARYOPHARM THERAPEUTICS INC / KPTI FAQ
Can you describe the business of KARYOPHARM THERAPEUTICS INC?
Karyopharm Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. The company is headquartered in Newton, Massachusetts and currently employs 279 full-time employees. The company went IPO on 2013-11-06. The firm is engaged in the discovery, development and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. The company is developing and commercializing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead asset, XPOVIO (selinexor), is marketed in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. The firm is engaged in evaluating selinexor in certain hematological and solid tumor malignancies, including endometrial cancer, mycosis fungoides (MF) and diffuse large B-cell lymphoma (DLBCL). The Company’s product candidate, eltanexor, is an oral SINE compound like selinexor, that selectively blocks the nuclear export protein XPO1.
What is the current price of KPTI stock?
The current stock price of KPTI is 6.92 USD. The price decreased by -1.84% in the last trading session.
Does KARYOPHARM THERAPEUTICS INC pay dividends?
KPTI does not pay a dividend.
What is the ChartMill technical and fundamental rating of KPTI stock?
KPTI has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
How is the market expecting KPTI stock to perform?
12 analysts have analysed KPTI and the average price target is 14.89 USD. This implies a price increase of 115.2% is expected in the next year compared to the current price of 6.92.
Who owns KARYOPHARM THERAPEUTICS INC?
You can find the ownership structure of KARYOPHARM THERAPEUTICS INC (KPTI) on the Ownership tab.